By taking advantage of highly proliferating CART cells during CRS, we designed CART to autonomously secrete anti-IL6 scFv and IL1RA for blocking IL6 and IL1 signalings during CART therapy as illustrated in Fig. 1a, b. Here, IL1R1 is linked to congenital rubella syndrome.